Tirzepatide Use Linked to Lower Risk for Diabetic Retinopathy
FRIDAY, Feb. 20, 2026 — For patients with diabetes and overweight or obesity, tirzepatide use is associated with a lower incidence of new or progressive diabetic retinopathy (DR) and fewer complications, according to a study published online Jan…
Satisfaction With Semaglutide Driven by Effective Weight Loss
FRIDAY, Feb. 20, 2026 — Satisfaction with semaglutide (Ozempic) is mainly driven by effective weight loss despite gastrointestinal side effects, according to a study published in the February issue of the Journal of Medical Internet…
What’s next for GLP-1s?
Now that GLP-1 drugs have revolutionized how millions of Americans treat obesity and Type 2 diabetes, scientists are exploring the benefits of using the drugs for a host of other chronic diseases—many with few treatment options—such as heart failure, chronic liver disease, obstructive sleep apnea, and even substance use disorders.
Gordon Ramsay slams ‘stupid’ Ozempic-inspired restaurant menu trend
Gordon Ramsay, celebrity chef, slams restaurants for creating Mounjaro-minded menus, calling the GLP-1-inspired dining trend “stupid” and “embarrassing.”
Redefining Obesity Treatment Beyond GLP-1 Limits
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
Opinion: My biggest GLP-1 ethical problem: patients who don’t want to stop
Some GLP-1 patients are begging to stay on the drugs just a little bit longer, presenting an ethical dilemma for doctors.
Risk for Nonscarring Hair Loss Increased in Association With GLP-1 Receptor Agonist Use
WEDNESDAY, Feb. 18, 2026 — The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, according to a study published online Feb. 9 in the Journal of the American Academy of…
Lilly’s Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
🤝 Lilly’s Zepbound plus Taltz combo: The company said the drugs, when taken together, helped 27.1% of patients with plaque psoriasis and obesity (or who were overweight) achieve full skin clearance …
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop
(MedPage Today) — The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition and even the comeback of scurvy. (The Hill)
An $80-per-month produce prescription subsidy failed to improve cardiometabolic health…
Taking the next shot: GLP-1 research and the new era of weight loss
Soaring in popularity, GLP-1 medications—from weekly injections to newly available pills—are rapidly reshaping how Americans think about weight loss. In fact, a recent poll finds 1 in 8 adults are now taking medications like Ozempic or Wegovy for weight loss or chronic conditions, and use is expected to keep rising.